ropidoxuridine: Clinical Trials

5 trials of ropidoxuridine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 2 terminated, 1 completed. 4 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Active not recruiting 2, Completed 1, Terminated 1
Phase 21Terminated 1

Follow ropidoxuridine: new trials by email Literature Review of ropidoxuridine trials Research Report on ropidoxuridine

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
Ropidoxuridine - Glioblastoma, IDH-wildtype
Phase 2TerminatedShuttle Pharmaceuticals, Inc.302024-09-022025-12-18
Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer
Capecitabine, Radiation Therapy, Ropidoxuridine - Locally Advanced Rectal Carcinoma, Rectal Adenocarcinoma
Phase 1TerminatedNational Cancer Institute (NCI)12021-03-172025-02-26
Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Phase 1Active not recruitingNational Cancer Institute (NCI)112017-05-082026-11-18
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Bile Duct Carcinoma, Stage II Esophageal Cancer AJCC v7
Phase 1Active not recruitingNational Cancer Institute (NCI)192016-02-012026-11-18
An Early Phase I Study of IPdR Absorption, Metabolism, and Safety in Patients With Advanced Solid Tumors and Lymphomas
IPdR - Neoplasms, Lymphoma
Phase 1CompletedNational Cancer Institute (NCI)102010-10-262018-10-18

Conditions studied

Rectal Neoplasms (2)  ·  Brain Neoplasms (1)  ·  Colonic Neoplasms (1)  ·  Esophageal Neoplasms (1)  ·  Glioblastoma (1)  ·  Hematologic Neoplasms (1)  ·  Liver Neoplasms (1)  ·  Lymphoma (1)  ·  Neoplasms (1)  ·  Stomach Neoplasms (1)

Sponsors

National Cancer Institute (NCI) (4)  ·  Shuttle Pharmaceuticals, Inc. (1)

Countries

United States (5)

Top investigators

Charles Kunos (1)  ·  Pranshu Mohindra (1)  ·  Shivaani Kummar, M.D. (1)  ·  Timothy J Kinsella (1)

Results publications

PMID 37369852

NIH funding

UM1CA186644 (1), UM1CA186686 (1), UM1CA186691 (1), UM1CA186712 (1), UM1CA186716 (1)